Showing results (1-10 of 214) with videos related to
Sort By:
Pageof 22
Biometrics|January 13, 2006
Goodness-of-fit methods for generalized linear mixed modelsZhiying Pan, D Y LinBiometrics|November 15, 2019
Design and analysis of bridging studies with prior probabilities on the null and alternative hypothesesDonglin Zeng, Zhiying Pan, D Y LinJournal of Glaucoma|May 24, 2011
Longitudinal changes in anterior chamber configuration in eyes with open-angle glaucoma and associated factorsZhiying Pan, Toshie Furuya, Kenji KashiwagiJournal of Biopharmaceutical Statistics|June 9, 2022
A Bayesian group sequential design for randomized biosimilar clinical trials with adaptive information borrowing from historical dataWen Zhang, Zhiying Pan, Ying YuanContemporary Clinical Trials|September 10, 2021
Elastic meta-analytic-predictive prior for dynamically borrowing information from historical data with application to biosimilar clinical trialsWen Zhang, Zhiying Pan, Ying YuanCurrent Eye Research|February 17, 2012
Role of retinal glial cell glutamate transporters in retinal ganglion cell survival following stimulation of NMDA receptorToshie Furuya, Zhiying Pan, Kenji KashiwagiTherapeutic Innovation & Regulatory Science|April 2, 2021
Design and Analysis of a Biosimilar Bridging Study with a Prediction Interval-Based Consistency TestZhiying Pan, Wenying Huang, Jianhong Pan, et al.Cancer Chemotherapy and Pharmacology|September 3, 2017
A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult menRichard Markus, Vincent Chow, Zhiying Pan, et al.Cancer Chemotherapy and Pharmacology|October 1, 2018
A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjectsVladimir Hanes, Vincent Chow, Zhiying Pan, et al.Cancer Chemotherapy and Pharmacology|November 22, 2017
Correction to: A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult menRichard Markus, Vincent Chow, Zhiying Pan, et al.Pageof 22